Business context and reporting period
The supplied filing is AcelRx Pharmaceuticals, Inc.’s unaudited Form 10-Q for the quarter and six months ended June 30, 2018. This does not match the request metadata identifying Talphera, Inc.; verify the issuer before relying on this summary.
AcelRx is developing and commercializing sublingual sufentanil products for acute pain in medically supervised settings. DSUVIA was under FDA review; DZUVEO received European Commission marketing approval in June 2018; Zalviso was approved in Europe and marketed there by Grünenthal.
Financial results and liquidity
Amounts below are in U.S. dollars. Financial statement amounts are converted from thousands to millions.
| Metric | Three months ended June 30, 2018 | Six months ended June 30, 2018 |
|---|---|---|
| Revenue | $0.8 million | $1.2 million |
| Operating expenses | $8.0 million | $16.6 million |
| Operating loss | $7.2 million | $15.4 million |
| Net loss | $10.5 million | $22.1 million |
| Net loss per share, basic and diluted | $0.20 | $0.43 |
| Cash used in operating activities | Not separately reported for the quarter | $13.8 million |
- Q2 revenue fell 69% from $2.7 million in 2017; first-half revenue fell 80% from $5.8 million. Management attributed the decline mainly to Grünenthal reducing existing Zalviso inventory purchases.
- Q2 net loss narrowed from $13.1 million to $10.5 million; first-half net loss narrowed from $28.6 million to $22.1 million, primarily amid lower operating expenses.
- Cost of goods sold was $0.7 million in Q2 and $1.9 million for the half. Management said Zalviso sales to Grünenthal were generating negative gross margins, and expected negative gross margins for the foreseeable future.
- At June 30, cash and cash equivalents were $33.3 million and short-term investments were $16.8 million, totaling $50.1 million, down from $60.5 million at year-end 2017. First-half cash used in operations was $13.8 million; investing used $9.6 million; financing provided $3.8 million.
- Total liabilities were $113.6 million versus assets of $64.6 million, leaving a stockholders’ deficit of $49.0 million. Hercules debt was $15.7 million, with a scheduled March 2020 maturity. The royalty monetization liability to PDL was $89.3 million, including a $5.8 million non-cash interest charge for the first half.
- First-half financing included $7.4 million net proceeds from at-the-market share sales and $3.8 million of debt principal payments. Common shares outstanding were 53.3 million at June 30; the filing reports 60.6 million outstanding as of July 26.
Material changes, outlook and risks
- Management estimated existing capital resources would fund operations through at least the end of the third quarter of 2019, based on its operating plan and before considering subsequent financing. The filing cautions that this estimate could change and that additional capital will be needed over the longer term.
- After quarter-end, on July 16, AcelRx completed a public offering of 7,272,727 shares at $2.75 per share, with estimated net proceeds of $18.7 million. Underwriters also received a 30-day option to buy up to 1,090,909 additional shares. This subsequent financing is not included in June 30 cash balances.
- The FDA assigned November 3, 2018 as the PDUFA goal date for the resubmitted DSUVIA NDA. The filing notes that approval is uncertain and further FDA requests could delay or prevent commercialization. AcelRx planned to resubmit the Zalviso NDA in the second half of 2018; approval could be affected by FDA concerns about device errors and inadvertent tablet dispensing.
- Management planned to prepare for potential U.S. DSUVIA commercialization and expected 2018 general and administrative expense to increase versus 2017. It expected Zalviso collaboration revenue from product sales to decline during 2018 before modestly increasing in 2019, and anticipated minimal Zalviso royalty revenue in 2018.
- European DZUVEO commercialization remained dependent on finding a strategic partner; no agreement had been signed. Comparator studies might be needed to support premium reimbursement in some countries.
- Other key risks include ongoing operating losses and financing needs, dilution from equity issuance, opioid-related regulatory and market restrictions, reliance on third-party manufacturers and a limited qualified supply chain, Grünenthal’s commercialization performance, and potential inability to achieve lower manufacturing costs. The company reported no material legal proceedings, and management concluded disclosure controls were effective.
Important facts for investors to verify
- Confirm that this AcelRx filing—not a Talphera filing—is the intended document.
- Check the FDA’s DSUVIA review outcome against the November 3, 2018 goal date, and the timing and status of the planned Zalviso resubmission.
- Assess cash use and financing needs against the stated runway estimate; distinguish June 30 liquidity from the July offering proceeds and any underwriter option exercise.
- Review future Zalviso sales, Grünenthal inventory levels, royalty receipts after the PDL monetization, and whether product supply can reach margins consistent with management’s expectations.
- Track DZUVEO’s European partner search, reimbursement requirements, and the potential costs and timing of comparator studies.